Phenol, pentachloro-

RTECS #

SM6300000

CAS #

87-86-5
See: NMAM or OSHA Methods

Updated

December 2018

Molecular Weight

266.32

Molecular Formula

C₆HCl₅O

Synonyms

1-Hydroxypentachlorobenzene
2,3,4,5,6-Pentachlorophenol
AD 73
Chem-Penta
Chem-Tol
Chlon
Chlorophen
CM 613
CP 1309
Dow pentachlorophenol DP-2 antimicrobial
Dowicide 7
Dowicide EC-7
Durotox
EP 30
Fungifen
Grundier arbezol
Lauxtol
Lauxtol A
Liroprem
MB 333
NCI-C54933
NCI-C55378
NCI-C56655
PCP
PCP (pesticide)
Penchlorol
Penta
Penta ready
Penta WR
Pentachloorfenol (Dutch)
Pentachlorofenol
Pentachlorofenolo
Pentachlorophenol
Pentachlorophenol (ACGIH:OSHA)
Pentachlorophenol, DP-2
Pentachlorophenol, EC-7
Pentachlorophenol, technical-grade
Pentachlorphenol
Pentachlorphenol (German)
Pentaclorofenolo (Italian)
Pentacon
Penta-kil
Penwar
Peratox
Permacide
Permagard
Permasan
Permatox DP-2
Permatox penta
Permite
Pol Nu
Pole topper fluid
Preventol P
RCRA waste number U242
Santophen 20
Thompson's wood fix
Weedone
Witophen P
Woodtreat A

Skin and Eye Irritation and References

Route/Organism	Dose	Effect	Reference
eye /rabbit	100 µL/24H	mild	NTIS** OTS0546023
skin /rabbit	10 mg/24H open irritation test	mild	AIHAAP 23,95,1962

Mutation Data and Reference

System Test	Route/Organism/Tissue	Dose	Reference
Cytogenetic Analysis	ovary/hamster	80 mg/L	EMMUEG 10(Suppl 10),1,1987
Cytogenetic Analysis	fibroblast/hamster	300 mg/L (-enzymatic activation step)	HBPTO* 2,1491,2001
DNA adduct	oral/rat	6000 mg/kg/8W	FCTOD7 74,28,2014
DNA Damage	Ascites tumor/human	50 mg/L/2H	FCTOD7 42,1323,2004
DNA Damage	multiple/non-mammalian species	100 µg/L/2H	MUREAV 605,78,2006
DNA Damage	fibroblast/human	1 mmol/L/1H (+enzymatic activation step)	MUREAV 701,103,2010
DNA Damage	lymphocyte/human	0.75 mmol/L/1H (+enzymatic activation step)	MUREAV 701,103,2010
DNA Damage	fibroblast/hamster	1.5 mmol/L/1H (+enzymatic activation step)	MUREAV 701,103,2010
DNA Damage	liver/human	1.35 mmol/L/1H (+enzymatic activation step)	MUREAV 701,103,2010
DNA Damage	HeLa cell/human	1.35 mmol/L/1H (+enzymatic activation step)	MUREAV 701,103,2010
DNA Damage	multiple/other insects	25 µg/L/24H	MUREAV 758,41,2013
DNA Damage	multiple/other insects	25 µg/L/96H-continuous	MUREAV 758,41,2013
gene conversion and mitotic recombination	/Saccharomyes cerevisiae	190 µmol/L	IARCCD 10,161,1974
micronucleus test	multiple/non-mammalian species	10 µg/L/24H	MUREAV 605,78,2006
morphological transform	embryo/hamster	100 mg/L	AETODY 1,241,1980
morphological transform	fibroblast/mouse	0.01 mg/L/21D (-enzymatic activation step)	EMMUEG 37,231,2001
mutation in microorganisms	/Other microorganisms	40 mg/L	HBPTO* 2,1491,2001
mutation in microorganisms	/Salmonella typhimurium	40 nmol/plate (-enzymatic activation step)	AIDZAC 10,305,1982
mutation in microorganisms	/Saccharomyes cerevisiae	400 mg/L (-enzymatic activation step)	EVSRBT 12,325,1978
other mutation test systems	oral/mouse	30 mg/kg	MUREAV 343,157,1995
other mutation test systems	/Other microorganisms	10 mg/L	EESADV 13,7,1987
sister chromatid exchange	ovary/hamster	3 mg/L	EMMUEG 10(Suppl 10),1,1987
specific locus test	intraperitoneal/mouse	50 mg/kg	EVSRBT 12,325,1978
specific locus test	multiple/other fish	5 µg/L/10D-continuous	MUREAV 609,92,2006

Reproductive Effects Data and References

Route/Organism	Dose	Effect	Reference
inhalation/mouse	0.15 mg/m³ (122D prior to copulation)	Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants) Reproductive: Effects on newborn: Other postnatal measures or effects	VCVGK* -,258,1994
oral/rat	50 mg/kg (6-15D pregnant)	Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) Reproductive: Effects on newborn: Sex ratio Reproductive: Specific developmental abnormalities: Musculoskeletal system	HBPTO* 2,1496,2001
oral/rat	5 gm/kg (26W male/26W prior to copulation/0-20D pregnant)	Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) Reproductive: Other effects to embryo or fetus	HBPTO* 2,1496,2001
oral/rat	800 mg/kg (6-15D pregnant)	Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants) Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus)	IJTOFN 20,353,2001
oral/rat	3300 mg/kg (multigeneration)	Reproductive: Effects on fertility: Pre- implantation mortality (e.g., reduction in number of implants per female; total number of implants per corpora lutea) Reproductive: Specific developmental abnormalities: Urogenital system Reproductive: Effects on newborn: Germ cell effects (in offspring)	IJTOFN 21,301,2002
oral/rat	6600 mg/kg (multigeneration)	Reproductive: Effects on newborn: Live birth index (Litter size (e.g., # fetuses per litter; measured after birth) Reproductive: Effects on newborn: Viability index (e.g., # alive at day 4 per # born alive) Reproductive: Effects on newborn: Weaning or lactation index (e.g., # alive at weaning per # alive at day 4)	IJTOFN 21,301,2002
oral/rat	60 mg/kg (9D pregnant)	Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus)	DABBBA 37,1184,1976
oral/rat	50 mg/kg (6-15D pregnant)	Reproductive: Specific developmental abnormalities: Musculoskeletal system	TXAPA9 28,151,1974
oral/rat	4 gm/kg (77D pre-28D after birth)	Reproductive: Effects on newborn: Weaning or lactation index (e.g., # alive at weaning per # alive at day 4) Reproductive: Effects on newborn: Growth statistics (e.g., reduced weight gain)	TXAPA9 41,138,1977
oral/rat	120 mg/kg (8-11D pregnant)	Reproductive: Specific developmental abnormalities: Homeostasis	TXAPA9 28,151,1974
oral/man	124 mg/kg (multigeneration)	Reproductive: Effects on newborn: Delayed effects	JRPFA4 113,95,1998
subcutaneous/mouse	450 mg/kg (6-14D pregnant)	Reproductive: Effects on embryo or fetus: Fetal death	NTIS** PB223-160
unreported route/rat	5 mg/kg (8D pregnant)	Reproductive: Effects on newborn: Growth statistics (e.g., reduced weight gain) Reproductive: Effects on newborn: Other postnatal measures or effects	VCVGK* -,249,1994
unreported route/rat	5 mg/kg (9D pregnant)	Reproductive: Effects on newborn: Growth statistics (e.g., reduced weight gain) Reproductive: Effects on newborn: Other postnatal measures or effects	VCVGK* -,249,1994
unreported route/rat	5 mg/kg (10D pregnant)	Reproductive: Effects on newborn: Growth statistics (e.g., reduced weight gain) Reproductive: Effects on newborn: Other postnatal measures or effects	VCVGK* -,249,1994
unreported route/rat	5 mg/kg (11D pregnant)	Reproductive: Effects on newborn: Growth statistics (e.g., reduced weight gain) Reproductive: Effects on newborn: Other postnatal measures or effects	VCVGK* -,249,1994
unreported route/rat	5 mg/kg (12D pregnant)	Reproductive: Effects on newborn: Growth statistics (e.g., reduced weight gain) Reproductive: Effects on newborn: Other postnatal measures or effects	VCVGK* -,249,1994
unreported route/rat	5 mg/kg (13D pregnant)	Reproductive: Effects on newborn: Growth statistics (e.g., reduced weight gain) Reproductive: Effects on newborn: Other postnatal measures or effects	VCVGK* -,249,1994

Tumorigenic Data and References

Route/Organism	Dose	Effect	Reference
oral/mouse	lowest published toxic dose: 8652 mg/kg/103W- continuous	Tumorigenic: Carcinogenic by RTECS criteria Liver: Tumors Endocrine: Adrenal cortex tumors	NTIS** PB89-216536/AS
oral/mouse	lowest published toxic dose: 17304 mg/kg/103W- continuous	Tumorigenic: Carcinogenic by RTECS criteria Liver: Tumors	NTIS** PB89-216536/AS
oral/mouse	lowest published toxic dose: 51912 mg/kg/103W- continuous	Tumorigenic: Neoplastic by RTECS criteria Endocrine: Adrenal cortex tumors Blood: Tumors	NTIS** PB89-216536/AS
oral/mouse	lowest published toxic dose: 17304 mg/kg/103W- continuous	Tumorigenic: Neoplastic by RTECS criteria Blood: Tumors	NTIS** PB89-216536/AS
oral/mouse	lowest published toxic dose: 8736 mg/kg/2Y- continuous	Tumorigenic: Carcinogenic by RTECS criteria Endocrine: Tumors	NTPTR* NTP-TR-349,1989
oral/rat	lowest published toxic dose: 21840 mg/kg/52W- continuous	Tumorigenic: Equivocal tumorigenic agent by RTECS criteria Olfaction: Tumors	NTIS** PB99-152878
oral/rat	lowest published toxic dose: 21.9 gm/kg/1Y- continuous	Tumorigenic: Neoplastic by RTECS criteria	HBPTO* 2,1489,2001
subcutaneous/mouse	lowest published toxic dose: 46 mg/kg	Tumorigenic: Equivocal tumorigenic agent by RTECS criteria Lung, Thorax, or Respiration: Tumors Liver: Tumors	NTIS** PB223-159

Acute Toxicity Data and References

Route/Organism	Dose	Effect	Reference
In Vitro/Chicken, neurons	Inhibitor Concentration (50 percent kill): 119 µmol/L/21H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	TIVIEQ 7,653,1993
In Vitro/Chicken, neurons	Inhibitor Concentration (10 percent kill): 38 µmol/L/21H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	TIVIEQ 7,653,1993
In Vitro/Chicken, neurons	Inhibitor Concentration (50 percent kill): 47 µmol/L/20H	In Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc.	TIVIEQ 7,653,1993
In Vitro/Chicken, neurons	Inhibitor Concentration (10 percent kill): 33 µmol/L/20H	In Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc.	TIVIEQ 7,653,1993
In Vitro/Human, endocrine tumor	Inhibitor Concentration Low: 0.4 µmol/L/48H	Endocrine: Other changes	TXCYAC 282,146,2011
In Vitro/Human, endocrine tumor	Inhibitor Concentration Low: 3.4 µmol/L/48H	Endocrine: Other changes In Vitro Toxicity Studies: Other assays Biochemical: Metabolism (intermediary): Effect on cyclic nucleotides	TXCYAC 282,146,2011
In Vitro/Human, kidney tumor	Inhibitor Concentration (50 percent kill): 67.9 mg/L	In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc.	TIVIEQ 27,1347,2013
In Vitro/Human, liver tumor	Inhibitor Concentration (50 percent kill): 420 mg/L	In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc.	TIVIEQ 27,1347,2013
In Vitro/Human, liver tumor	Inhibitor Concentration (50 percent kill): 60.4 µmol/L/48H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	TXAPA9 266,335,2013
In Vitro/Human, liver tumor	Inhibitor Concentration (50 percent kill): 13.9 mg/L/24H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	TIVIEQ 27,1347,2013
In Vitro/Human, lymphocyte	Inhibitor Concentration (30 percent kill): 22 mg/L/45H	In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc.	TIVIEQ 29,901,2015
In Vitro/Human, lymphocyte	Inhibitor Concentration (50 percent kill): 21 mg/L/45H	In Vitro Toxicity Studies: Other assays	TIVIEQ 29,901,2015
In Vitro/Human, monocyte	Inhibitor Concentration (20 percent kill): 31 µmol/L/24H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	TOLED5 199,51,2010
In Vitro/Human, monocyte	Inhibitor Concentration (20 percent kill): 31 µmol/L/2H	In Vitro Toxicity Studies: Other assays	TOLED5 199,51,2010
In Vitro/Human, neuroblastoma	Inhibitor Concentration Low: 1.9 µmol/L/4M	In Vitro Toxicity Studies: Membrane currents	TXAPA9 245,191,2010
In Vitro/Human, neuroblastoma	Inhibitor Concentration (50 percent kill): 65 µmol/L/15M	In Vitro Toxicity Studies: Other assays	TXAPA9 245,191,2010
In Vitro/Human, neuroblastoma	Inhibitor Concentration (50 percent kill): 860 µmol/L/60M	Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: True cholinesterase	TXAPA9 245,191,2010
In Vitro/Human, skin	Inhibitor Concentration (50 percent kill): 0.679 mg/L/48H	In Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc.	TIVIEQ 27,1347,2013
In Vitro/Mouse, fibroblast	Inhibitor Concentration (50 percent kill): 19.1 mg/L/48H	In Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc.	TIVIEQ 27,1347,2013
In Vitro/Mouse, fibroblast	Inhibitor Concentration (50 percent kill): 23.1 mg/L/24H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	TIVIEQ 27,1347,2013
In Vitro/Non-mammalian species, fibroblast	Inhibitor Concentration (50 percent kill): 0.24 mmol/L/24H	In Vitro Toxicity Studies: Cell counting	TIVIEQ 7,537,1993
In Vitro/paa	Inhibitor Concentration Low: 0.357 µmol/L/44H	In Vitro Toxicity Studies: Other assays	TIVIEQ 27,1416,2013
In Vitro/Rat, liver	Inhibitor Concentration (50 percent kill): 22.1 mg/L/24H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	TIVIEQ 27,1347,2013
inhalation/mouse	lethal concentration (50 percent kill): 225 mg/m³	Behavioral: Excitement Behavioral: Muscle contraction or spasticity Lung, Thorax, or Respiration: Dyspnea	GTPZAB 13(9),58,1969
inhalation/mouse	lethal concentration (50 percent kill): 225 mg/m³	Cardiac: Other changes Liver: Other changes Kidney, Ureter, and Bladder: Other changes	VCVGK* -,248,1994
inhalation/rat	lethal concentration (50 percent kill): 335 mg/m³	Cardiac: Other changes Liver: Other changes Kidney, Ureter, and Bladder: Other changes	VCVGK* -,248,1994
inhalation/rat	lethal concentration (50 percent kill): 200 mg/m³		HBPTO* 2,1229,2001
inhalation/rat	lethal concentration (50 percent kill): 355 mg/m³	Behavioral: Excitement Behavioral: Muscle contraction or spasticity Lung, Thorax, or Respiration: Dyspnea	GTPZAB 13(9),58,1969
intraperitoneal/mouse	lethal dose (50 percent kill): 32 mg/kg		ARTODN 40,63,1978
intraperitoneal/mouse	lowest published toxic dose: 120 mg/kg	Immunological Including Allergic: Decrease in humoral immune response	TXCYAC 36,307,1985
intraperitoneal/mouse	lowest published lethal dose: 250 mg/kg		VCVGK* -,257,1994
intraperitoneal/rabbit	lowest published lethal dose: 135 mg/kg		HBTXAC 5,123,1959
intraperitoneal/rat	lethal dose (50 percent kill): 56 mg/kg	Behavioral: Convulsions or effect on seizure threshold Lung, Thorax, or Respiration: Dyspnea Nutritional and Gross Metabolic: Body temperature increase	BJPCAL 13,20,1958
intraperitoneal/rat	lowest published toxic dose: 1.86 mg/kg	Endocrine: Other changes	TXCYAC 67,107,1991
intraperitoneal/rat	lethal dose (50 percent kill): 60 mg/kg		HBPTO* 2,1486,2001
intraperitoneal/rat	lethal dose (50 percent kill): 56 mg/kg	Cardiac: Other changes Liver: Other changes Kidney, Ureter, and Bladder: Other changes	VCVGK* -,246,1994
oral/duck	lethal dose (50 percent kill): 380 mg/kg		HBPTO* 2,1229,2001
oral/gerbil	lethal dose (50 percent kill): 294 mg/kg		ARTODN 40,63,1978
oral/hamster	lethal dose (50 percent kill): 168 mg/kg		TXAPA9 48,A192,1979
oral/man	lowest published lethal dose: 401 mg/kg	Behavioral: Change in motor activity (specific assay) Skin and Appendages: Other: Sweating Nutritional and Gross Metabolic: Body temperature increase	EESADV 1,343,1977
oral/mouse	lethal dose (50 percent kill): 36 mg/kg		ARTODN 40,63,1978
oral/mouse	lethal dose (50 percent kill): 117 mg/kg	Behavioral: Somnolence (general depressed activity)	TOLED5 29,39,1985
oral/mouse	lethal dose (50 percent kill): 30 mg/kg	Cardiac: Other changes Liver: Other changes Kidney, Ureter, and Bladder: Other changes	VCVGK* -,246,1994
oral/mouse	lowest published toxic dose: 30 mg/kg	Liver: Other changes Biochemical: Metabolism (intermediary): Other proteins	TOSCF2 73,26,2003
oral/rabbit	lethal dose (50 percent kill): 200 mg/kg	Cardiac: Other changes Liver: Other changes Kidney, Ureter, and Bladder: Other changes	VCVGK* -,246,1994
oral/rabbit	lowest published lethal dose: 70 mg/kg		VCVGK* -,249,1994
oral/rabbit	lowest published lethal dose: 70 mg/kg	Behavioral: Muscle weakness Vascular: BP elevation not characterized in autonomic section Kidney, Ureter, and Bladder: Urine volume increased	JPETAB 76,104,1942
oral/rat	lethal dose (50 percent kill): 27 mg/kg	Vascular: BP elevation not characterized in autonomic section Endocrine: Hyperglycemia Nutritional and Gross Metabolic: Body temperature increase	JPETAB 76,104,1942
oral/rat	lethal dose (50 percent kill): 27 mg/kg	Cardiac: Other changes Liver: Other changes Kidney, Ureter, and Bladder: Other changes	VCVGK* -,246,1994
oral/rat	lowest published toxic dose: 5 mg/kg	Liver: Other changes Biochemical: Metabolism (intermediary): Other proteins	TOSCF2 73,26,2003
oral/rat	lethal dose (50 percent kill): 50 mg/kg		VCVGK* -,249,1994
skin/rabbit	lowest published lethal dose: 40 mg/kg		VCVGK* -,249,1994
skin/rabbit	lowest published lethal dose: 40 mg/kg	Behavioral: Muscle weakness Vascular: BP elevation not characterized in autonomic section Kidney, Ureter, and Bladder: Urine volume increased	JPETAB 76,104,1942
skin/rat	lethal dose (50 percent kill): 96 mg/kg	Behavioral: Excitement Behavioral: Muscle contraction or spasticity Lung, Thorax, or Respiration: Dyspnea	GTPZAB 13(9),58,1969
skin/rat	lethal dose (50 percent kill): 26 mg/kg	Cardiac: Other changes Liver: Other changes Kidney, Ureter, and Bladder: Other changes	VCVGK* -,246,1994
subcutaneous/Dog	lowest published lethal dose: 135 mg/kg		HBTXAC 5,123,1959
subcutaneous/rabbit	lowest published lethal dose: 70 mg/kg	Behavioral: Muscle weakness Vascular: BP elevation not characterized in autonomic section Kidney, Ureter, and Bladder: Urine volume increased	JPETAB 76,104,1942
subcutaneous/rabbit	lowest published lethal dose: 70 mg/kg		VCVGK* -,249,1994
subcutaneous/rat	lethal dose (50 percent kill): 100 mg/kg	Cardiac: Other changes Liver: Other changes Kidney, Ureter, and Bladder: Other changes	VCVGK* -,246,1994
Tank with water/Other invertebrate	lethal concentration (50 percent kill): 0.92 mg/L/24H		TIVIEQ 32,271,1995
Tank with water/Zebrafish	lowest published toxic concentration: 50 µg/mL/8H	Reproductive: Other effects to embryo or fetus	TXAPA9 277,183,2014
unreported route/Dog	lethal dose (50 percent kill): 70 mg/kg		PHPHA6 1,3,1953
unreported route/frog	lethal dose (50 percent kill): 36 mg/kg		PHPHA6 1,3,1953
unreported route/guinea pig	lethal dose (50 percent kill): 100 mg/kg		PHPHA6 1,3,1953

Other Multiple Dose Data and References

Route/Organism	Dose	Effect	Reference
inhalation/rabbit	lowest published toxic concentration: 29 mg/m³/4H/15D- intermittent	Brain and Coverings: Other degenerative changes Liver: Other changes Blood: Normocytic anemia	VCVGK* -,249,1994
inhalation/rabbit	lowest published toxic concentration: 29 mg/m³/4H/60D- intermittent	Lung, Thorax, or Respiration: Chronic pulmonary edema or congestion Gastrointestinal: Other changes Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field	VCVGK* -,249,1994
inhalation/rat	lowest published toxic concentration: 29 mg/m³/4H/60D- intermittent	Lung, Thorax, or Respiration: Chronic pulmonary edema or congestion Gastrointestinal: Other changes Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field	VCVGK* -,249,1994
inhalation/rat	lowest published toxic concentration: 29 mg/m³/4H/15D- intermittent	Brain and Coverings: Other degenerative changes Liver: Other changes Blood: Normocytic anemia	VCVGK* -,249,1994
oral/cattle	lowest published toxic dose: 2610 mg/kg/23W- continuous	Endocrine: Changes in thymus weight Blood: Changes in erythrocyte (RBC) count Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.)	TXAPA9 52,468,1980
oral/cattle	lowest published toxic dose: 2610 mg/kg/160D- intermittent	Liver: Other changes Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.)	TXAPA9 52,468,1980
oral/cattle	lowest published toxic dose: 2610 mg/kg/160D- intermittent	Lung, Thorax, or Respiration: Changes in lung weight Blood: Normocytic anemia Nutritional and Gross Metabolic: Weight loss or decreased weight gain	TXAPA9 52,468,1980
oral/mouse	lowest published toxic dose: 140 mg/kg/14D- intermittent	Immunological Including Allergic: Decrease in humoral immune response	HBPTO* 2,1499,2001
oral/mouse	lowest published toxic dose: 45 gm/kg/30D- continuous	Liver: Changes in liver weight Endocrine: Changes in spleen weight Nutritional and Gross Metabolic: Weight loss or decreased weight gain	NTPTR* NTP-TR-349,1989
oral/mouse	lowest published toxic dose: 1680 mg/kg/8W- continuous	Liver: Changes in liver weight Immunological Including Allergic: Decrease in humoral immune response Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Dehydrogenases	FAATDF 2,90,1982
oral/mouse	lowest published toxic dose: 10920 mg/kg/26W- continuous	Liver: Changes in liver weight Endocrine: Changes in spleen weight Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Transaminases	NTPTR* NTP-TR-349,1989
oral/mouse	lowest published toxic dose: 14168 mg/kg/23W- continuous	Tumorigenic: Facilitates action of known carcinogens	CRNGDP 24,1105,2003
oral/mouse	lowest published toxic dose: 728 mg/kg/2W- continuous	Liver: Other changes Liver: Changes in liver weight Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Transaminases	CRNGDP 24,1105,2003
oral/pig	lowest published toxic dose: 150 mg/kg/30D- intermittent	Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol) Blood: Changes in leukocyte (WBC) count	BECTA6 31,599,1983
oral/rabbit	lowest published toxic dose: 195 mg/kg/13D- intermittent	Nutritional and Gross Metabolic: Weight loss or decreased weight gain	IJTOFN 20,345,2001
oral/rabbit	lowest published toxic dose: 390 mg/kg/13D- intermittent	Behavioral: Food intake (animal)	IJTOFN 20,345,2001
oral/rat	lowest published toxic dose: 800 mg/kg/10D- intermittent	Behavioral: Food intake (animal) Nutritional and Gross Metabolic: Weight loss or decreased weight gain	IJTOFN 20,353,2001
oral/rat	lowest published toxic dose: 840 mg/kg/12W- continuous	Liver: Changes in liver weight Blood: Changes in erythrocyte (RBC) count Nutritional and Gross Metabolic: Weight loss or decreased weight gain	TXCYAC 2,141,1974
oral/rat	lowest published toxic dose: 84 mg/kg/28D- intermittent	Endocrine: Other changes Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol)	TOLED5 71,9,1994
oral/rat	lowest published toxic dose: 21840 mg/kg/2Y- continuous	Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol) Nutritional and Gross Metabolic: Weight loss or decreased weight gain Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Transaminases	EVSRBT 12,301,1978
oral/rat	lowest published toxic dose: 11.76 gm/kg/28W- continuous	Liver: Other changes	HBPTO* 2,1489,2001
oral/rat	lowest published toxic dose: 300 mg/kg/10D- intermittent	Nutritional and Gross Metabolic: Weight loss or decreased weight gain	HBPTO* 2,1496,2001
oral/rat	lowest published toxic dose: 8643 mg/kg/201D- continuous	Reproductive: Maternal effects: Uterus, cervix, vagina Nutritional and Gross Metabolic: Weight loss or decreased weight gain	HBPTO* 2,1496,2001
oral/rat	lowest published toxic dose: 2556 mg/kg/142D- intermittent	Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field	VCVGK* -,249,1994
oral/rat	lowest published toxic dose: 2060 mg/kg/57D- intermittent	Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field	VCVGK* -,249,1994
oral/rat	lowest published toxic dose: 3600 mg/kg/120D- intermittent	Liver: Hepatitis (hepatocellular necrosis), zonal Liver: Changes in liver weight Related to Chronic Data: Changes in ovarian weight	IJTOFN 21,301,2002
oral/rat	lowest published toxic dose: 7200 mg/kg/120D- intermittent	Gastrointestinal: Changes in structure or function of salivary glands Liver: Other changes Related to Chronic Data: Changes in uterine weight	IJTOFN 21,301,2002
oral/rat	lowest published toxic dose: 1000 mg/kg/100D- intermittent	Liver: Other changes Liver: Changes in liver weight Kidney, Ureter, and Bladder: Changes in kidney weight	IJTOFN 21,301,2002
oral/rat	lowest published toxic dose: 6000 mg/kg/100D- intermittent	Brain and Coverings: Changes in brain weight Liver: Hepatitis (hepatocellular necrosis), zonal Nutritional and Gross Metabolic: Weight loss or decreased weight gain	IJTOFN 21,301,2002
oral/rat	lowest published toxic dose: 6000 mg/kg/8W- intermittent	Liver: Other changes Nutritional and Gross Metabolic: Weight loss or decreased weight gain	FCTOD7 74,28,2014
subcutaneous/pig	lowest published toxic dose: 560 mg/kg/14D- intermittent	Reproductive: Maternal effects: Ovaries, fallopian tubes Reproductive: Maternal effects: Uterus, cervix, vagina Reproductive: Maternal effects: Menstrual cycle changes or disorders	REPTED 16,29,2002
unreported route/mouse	lowest published toxic dose: 60 mg/kg/3D- intermittent	Related to Chronic Data: Changes in uterine weight	TOXID9 54,262,2000

Reviews

Organization	Standard	Reference
American Conference of Governmental Industrial Hygienists (ACGIH)	Threshold Limit Value-time-weighted average 0.5 mg/m³ (skin)	DTLVS* TLV/BEI,2013
American Conference of Governmental Industrial Hygienists (ACGIH)	Threshold Limit Value-Confirmed animal carcinogen	DTLVS* TLV/BEI,2013
International Agency for Research on Cancer (IARC)	Cancer Review:Human Limited Evidence	IMEMDT 41,319,1986
International Agency for Research on Cancer (IARC)	Cancer Review:Animal Sufficient Evidence	IMEMDT 53,371,1991
International Agency for Research on Cancer (IARC)	Cancer Review:Animal Sufficient Evidence	IMEMDT 71,769,1999
International Agency for Research on Cancer (IARC)	Cancer Review:Animal Inadequate Evidence	IMEMDT 20,303,1979
International Agency for Research on Cancer (IARC)	Cancer Review:Human Inadequate Evidence	IMEMDT 53,371,1991
International Agency for Research on Cancer (IARC)	Cancer Review:Group 2B	IMEMDT 53,371,1991
TOXICOLOGY REVIEW		STEVA8 2,305,1974
TOXICOLOGY REVIEW		AIHAAP 43,799,1982
TOXICOLOGY REVIEW		TOLED5 127,101,2002
TOXICOLOGY REVIEW		MUREAV 567,227,2004
TOXICOLOGY REVIEW		ENTOX* -,567,2005
TOXICOLOGY REVIEW		ENTOX* -,343,2005
TOXICOLOGY REVIEW		JTEHD6 7,1,2004
TOXICOLOGY REVIEW		ADMOL* 1,85,2006
TOXICOLOGY REVIEW		REPTED 23,260,2007
TOXICOLOGY REVIEW		REPTED 26,185,2008
TOXICOLOGY REVIEW		HTOPA* 1,501,2002
TOXICOLOGY REVIEW		TPHSDY 29,361,2008
TOXICOLOGY REVIEW		FCTOD7 46,813,2008
TOXICOLOGY REVIEW		MUREAV 681,80,2009
TOXICOLOGY REVIEW		BLREV* 3,71,1989
TOXICOLOGY REVIEW		MUREAV 682,94,2009
TOXICOLOGY REVIEW		NEUCL* 15,711,1997
TOXICOLOGY REVIEW		NBREV* 5,1,1981
TOXICOLOGY REVIEW		MUREAV 705,184,2010
TOXICOLOGY REVIEW		TOLED5 202,36,2011
TOXICOLOGY REVIEW		TXCYAC 307,3,2013
TOXICOLOGY REVIEW		TXCYAC 307,123,2013
TOXICOLOGY REVIEW		MUREAV 767,67,2016
TOXICOLOGY REVIEW		TXCYAC 313,94,2013
TOXICOLOGY REVIEW		MUREAV 773,134,2017
TOXICOLOGY REVIEW		TIVIEQ 30,569,2015
TOXICOLOGY REVIEW		FCTOD7 105,429,2017
TOXICOLOGY REVIEW		TOLED5 254,52,2016
TOXICOLOGY REVIEW		RTOPDW 53,134,2009
TOXICOLOGY REVIEW		RTOPDW 58,395,2010

Standards and Regulations

Organization	Standard	Reference
Environmental Protection Agency (EPA) Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) 1988 PESTICIDE SUBJECT TO REGISTRATION OR RE-REGISTRATION		FEREAC 54,7740,1989
Environmental Protection Agency (EPA) Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) 1998 STATUS OF PESTICIDES	Supported	RBREV* -,197,1998
Mine Safety and Health Administration (MSHA) STANDARD-air	time-weighted average 0.5 mg/m³ (skin)	DTLVS* 3,198,1971
Occupational Exposure Limit IN ARGENTINA, BULGARIA, COLOMBIA, JORDAN check ACGIH TLV;
Occupational Exposure Limit IN SINGAPORE, VIETNAM check ACGIH TLV
Occupational Exposure Limit-AUSTRALIA	time-weighted average 0.5 mg/m³, JUL2008
Occupational Exposure Limit-BELGIUM	time-weighted average 0.5 mg/m³, Skin, MAR2002
Occupational Exposure Limit-DENMARK	time-weighted average 0.005 ppm (0.05 mg/m³), skin, carc, MAY2011
Occupational Exposure Limit-FINLAND	time-weighted average 0.5 mg/m³, short term exposure limit 1.5 mg/m³, skin, NOV2011
Occupational Exposure Limit-FRANCE	VME 0.5 mg/m³, Skin, C3 Carcinogen, FEB2006
Occupational Exposure Limit-HUNGARY	time-weighted average 0.001 mg/m³, Skin, SEP2000
Occupational Exposure Limit-ICELAND	time-weighted average 0.005 ppm (0.05 mg/m³), skin, NOV2011
Occupational Exposure Limit-JAPAN	Occupational Exposure Limit 0.5 mg/m³, skin, MAY2012
Occupational Exposure Limit-KOREA	time-weighted average 0.5 mg/m³, skin, 2006
Occupational Exposure Limit-MEXICO	time-weighted average 0.5 mg/m³;short term exposure limit 1.5 mg/m³ (skin), 2004
Occupational Exposure Limit-NEW ZEALAND	time-weighted average 0.5 mg/m³, skin, JAN2002
Occupational Exposure Limit-NORWAY	time-weighted average 0.05 ppm (0.5 mg/m³), JAN1999
Occupational Exposure Limit-PERU	time-weighted average 0,5 mg/m³, JUL2005
Occupational Exposure Limit-POLAND	MAC(time-weighted average) 0.5 mg/m³, MAC(short term exposure limit) 1.5 mg/m³, JAN1999
Occupational Exposure Limit-RUSSIA	time-weighted average 0.1 mg/m³, short term exposure limit 0.3 mg/m³, Skin, JUN2003
Occupational Exposure Limit-SWEDEN	time-weighted average 0.5 mg/m³;short term exposure limit 1.5 mg/m³, Skin, JUN2005
Occupational Exposure Limit-SWITZERLAND	MAK-week 0.005 ppm (0.05 mg/m³), carc 2, inhal, skin, JAN2011
Occupational Exposure Limit-THE NETHERLANDS	MAC-TGG 0.06 mg/m³, Skin, 2003
Occupational Exposure Limit-TURKEY	time-weighted average 0.5 mg/m³, Skin, JAN1993
Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Construction)	8H time-weighted average 0.5 mg/m³ (skin)	CFRGBR 29,1926.55,1994
Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Federal Contractors)	8H time-weighted average 0.5 mg/m³ (skin)	CFRGBR 41,50-204.50,1994
Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (General Industry)	8H time-weighted average 0.5 mg/m³ (skin)	CFRGBR 29,1910.1000,1994
Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Shipyards)	8H time-weighted average 0.5 mg/m³ (skin)	CFRGBR 29,1915.1000,1993

NIOSH Documentation and Surveillance

Organization	Standard	Reference
National Institute for Occupational Safety and Health (NIOSH) Recommended Exposure Level TO PENTACHLOROPHENOL-air	10H time-weighted average 0.5 mg/m³ (Sk)	NIOSH* DHHS #92-100,1992
National Occupational Exposure Survey 1983	Hazard Code 54160; Number of Industries 29; Total Number of Facilities 2248; Number of Occupations 38; Total Number of Employees Exposed 26806; Total Number of Female Employees Exposed 4191
National Occupational Hazard Survey 1974	Hazard Code 54160; Number of Industries 47; Total Number of Facilities 3548; Number of Occupations 42; Total Number of Employees Exposed 29154

Status in Federal Agencies

Organization	Reference
ATSDR TOXICOLOGY PROFILE (NTIS** PB/2001/109106/AS)
EPA GENETOX PROGRAM 1988, Negative: Histidine reversion-Ames test; S cerevisiae-homozygosis
EPA GENETOX PROGRAM 1988, Negative: Host-mediated assay; Mouse spot test
EPA GENETOX PROGRAM 1988, Positive: Cell transform.-SA7/SHE; S cerevisiae gene conversion
EPA GENETOX PROGRAM 1988, Positive: S cerevisiae-forward mutation
EPA TSCA Section 8(b) CHEMICAL INVENTORY
EPA TSCA Section 8(d) unpublished health/safety studies
EPA TSCA TEST SUBMISSION (TSCATS) DATA BASE, JANUARY 2001
NCI Carcinogenesis Studies (feed);clear evidence:mouse
NCI Carcinogenesis Studies (feed);equivocal evidence:rat
NIOSH Analytical Method, 1994: Pentachlorophenol, 5512; in blood, 8001; in urine, 8303
NTP 14th Report on Carcinogens,2016:Reasonably anticipated to be human carcinogen
On EPA IRIS database
OSHA ANALYTICAL METHOD #39

Page last reviewed: November 16, 2018

Content source: National Institute for Occupational Safety and Health